BiotechTube

Biktarvy 50Mg-200Mg-25Mg Tablet

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Harm Reduction

Conditions

Harm Reduction, HIV Infections, Drug Use

Trial Timeline

Mar 4, 2021 → Dec 31, 2023

NCT ID
NCT04650269

About Biktarvy 50Mg-200Mg-25Mg Tablet

Biktarvy 50Mg-200Mg-25Mg Tablet is a approved stage product being developed by Gilead Sciences for Harm Reduction. The current trial status is completed. This product is registered under clinical trial identifier NCT04650269. Target conditions include Harm Reduction, HIV Infections, Drug Use.

What happened to similar drugs?

5 of 5 similar drugs in Harm Reduction were approved

Approved (5) Terminated (0) Active (0)
✅tolterodine + mirabegronAstellas PharmaApproved
✅mirabegronAstellas PharmaApproved
✅Prograf + Tacrolimus HexalNovartisApproved
✅Aripiprazole + Aripiprazole + desvenlafaxine succinate sustained releasePfizerApproved
✅Tamoxifen + Tamoxifen and Desvenlafaxine Succinate Sustained ReleasePfizerApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04944654ApprovedTerminated
NCT04650269ApprovedCompleted

Competing Products

20 competing products in Harm Reduction

See all competitors
ProductCompanyStageHype Score
DFD-29 (Minocycline) Fasting + DFD-29 (Minocycline) Fed + Solodyn (Minocycline) FastingDr. Reddy's LaboratoriesPhase 1
26
DRL_PG + Pegfilgrastim Form A + Pegfilgrastim Form BDr. Reddy's LaboratoriesPhase 1
22
GP30341 capsules 200 mg + Standard therapyGEROPHARMPre-clinical
16
GP40221 + ozempicGEROPHARMPhase 1
19
GP40141 + NplateGEROPHARMPhase 1
15
Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mgGEROPHARMPhase 1
19
Rinsulin NPH + Humulin NPHGEROPHARMPre-clinical
16
Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)YuhanPhase 1
29
DS-8500a + ItraconazoleDaiichi SankyoPhase 1
29
Milademetan + Itraconazole + PosaconazoleDaiichi SankyoPhase 1
29
Pexidartinib + ProbenecidDaiichi SankyoPhase 1
29
DS-8500a + RosuvastatinDaiichi SankyoPhase 1
29
DS-8500aDaiichi SankyoPhase 1
29
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment CDaiichi SankyoPhase 1
29
tolterodine + mirabegronAstellas PharmaApproved
43
ASP3652Astellas PharmaPhase 1
29
ASP015K ER + ASP015K IRAstellas PharmaPhase 1
29
YM178 modified release (OCAS) + YM178 immediate release (IR)Astellas PharmaPhase 1
29
Isavuconazole + dextromethorphanAstellas PharmaPhase 1
29
mirabegron + metoprololAstellas PharmaPhase 1
29